Yahoo Finance

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in ...

RAHWAY, N.J., March 26, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved CAPVAXIVE ® ...
FiercePharma

Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing

After scoring approval as the world’s first pneumococcal disease vaccine made specifically for adults earlier this month, Merck’s Capvaxive passed the next test in its bid to take on Pfizer and its ...
Business Wire

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval ...
FiercePharma

As vaccines industry struggles, Merck's adult pneumococcal shot Capvaxive off to strong start

With vaccine sales on the decline across the industry, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. But in the third quarter, the company recorded encouraging sales ...
Business Wire

U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE™ ...
PharmiWeb

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 ...

Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit

Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s ...
Monthly Prescribing Reference

FDA Approves 21-Valent Pneumococcal Conjugate Vaccine Capvaxive

Credit: Merck. Capvaxive consists of pneumococcal polysaccharides from 21 serotypes, including 8 unique serotypes: 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B. Capvaxive consists of pneumococcal ...
Seeking Alpha

Merck says trial data for pneumonia shot Capvaxive shows promise in younger people

Merck (NYSE:MRK) announced late-stage trial data on Thursday suggesting that its Capvaxive vaccine, indicated for adults to prevent invasive pneumococcal disease and pneumonia, is also effective in ...
PharmiWeb

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in ...

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, ...
The Globe and Mail

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

CAPVAXIVE elicited immune responses to all 21 serotypes (or strains) as assessed by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days post-vaccination ...